Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baby Rinolo C.M. is a combination pharmaceutical product developed and marketed by Bruno Farmaceutici in Italy. It is formulated as an oral syrup containing paracetamol (acetaminophen) and chlorphenamine maleate. Paracetamol acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis, primarily within the central nervous system, while chlorphenamine maleate is a first-generation antihistamine that competitively antagonizes H1 receptors to reduce symptoms such as rhinorrhea and sneezing. Although the 'Baby' branding suggests use in infants, the medication is explicitly contraindicated for children under 3 years of age. It is indicated as an adjuvant treatment for acute febrile conditions of the upper respiratory tract and sinusitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baby Rinolo C.M..